• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ICOTINIB Drug Record

  • Summary
  • Interactions
  • Claims
  • ICOTINIB chembl:CHEMBL2087361 Antineoplastic

    Alternate Names:

    ICOTINIB
    BPI-2009H
    CONMANA®
    BPI-2009
    drugbank:11737
    chemidplus:610798-31-7
    pubchem.compound:22024915
    chembl:CHEMBL2087361

    Drug Info:

    Drug Class Kinase Inhibitors
    (2 More Sources)

    Publications:

    Hu P et al., 2015, Development of population pharmacokinetics model of icotinib with non-linear absorption characters in healthy Chinese volunteers to assess the CYP2C19 polymorphism and food-intake effect., Eur J Clin Pharmacol
    Ruan CJ et al., 2012, Effect of the CYP2C19 genotype on the pharmacokinetics of icotinib in healthy male volunteers., Eur J Clin Pharmacol
    Liang et al., 2014, Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations., PLoS ONE
    Chen et al., 2016, Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations., Onco Targets Ther
    Mills et al., 1990, Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells., J. Clin. Invest.
    Hu et al., 2014, A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC)., Lung Cancer
    Shao et al., 2014, Efficacy and safety of icotinib in Chinese patients with advanced non-small cell lung cancer after failure of chemotherapy., Chin. Med. J.
    Gu et al., 2013, Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer., Chin. J. Cancer Res.
  • ICOTINIB   EGFR

    Interaction Score: 1.84

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type decreased response

    PMIDs:
    24533047 27468240 2394835 25261231 24438614 23372346


    Sources:
    TALC MyCancerGenome JAX-CKB MyCancerGenomeClinicalTrial

  • ICOTINIB   CYP2C19

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25995169 22585284


    Sources:
    PharmGKB

  • MyCancerGenome: ICOTINIB

    • Version: 20-Jun-2017

    Alternate Names:
    BPI-2009H Development Name
    ICOTINIB Generic Name

    Drug Info:
    Drug Class Kinase Inhibitors

    Publications:

  • JAX-CKB: Icotinib

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Liang et al., 2014, Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations., PLoS ONE
    Chen et al., 2016, Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations., Onco Targets Ther
    Gu et al., 2013, Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer., Chin. J. Cancer Res.

  • PharmGKB: icotinib

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Hu P et al., 2015, Development of population pharmacokinetics model of icotinib with non-linear absorption characters in healthy Chinese volunteers to assess the CYP2C19 polymorphism and food-intake effect., Eur J Clin Pharmacol
    Ruan CJ et al., 2012, Effect of the CYP2C19 genotype on the pharmacokinetics of icotinib in healthy male volunteers., Eur J Clin Pharmacol

  • TALC: ICOTINIB

    • Version: 12-May-2016

    Alternate Names:
    ICOTINIB Primary Drug Name
    ICOTINIB Drug Generic Name
    CONMANA Drug Trade Name

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL2087361

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • MyCancerGenomeClinicalTrial: ICOTINIB

    • Version: 30-February-2014

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21